{"id":"budesonide-surfactant","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oral candidiasis"},{"rate":"5-10","effect":"Hoarseness"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Throat irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide works by binding to glucocorticoid receptors in airway epithelial cells, suppressing inflammatory cytokine production and reducing eosinophil infiltration. The surfactant component enhances pulmonary bioavailability and distribution of budesonide throughout the respiratory tract, improving therapeutic efficacy in treating airway inflammation.","oneSentence":"Budesonide is a corticosteroid that reduces airway inflammation, while the surfactant component improves drug delivery and reduces surface tension in the lungs.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:40:48.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance and reliever therapy)"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06855043","phase":"PHASE1, PHASE2","title":"Little Lungs Study","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-09","conditions":"Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome","enrollment":24},{"nctId":"NCT04545866","phase":"PHASE3","title":"The Budesonide in Babies (BiB) Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NICHD Neonatal Research Network","startDate":"2021-04-01","conditions":"Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme","enrollment":642},{"nctId":"NCT02907593","phase":"PHASE1, PHASE2","title":"Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial","status":"TERMINATED","sponsor":"Cynthia McEvoy","startDate":"2016-09","conditions":"Bronchopulmonary Dysplasia (BPD)","enrollment":25},{"nctId":"NCT06367881","phase":"PHASE1","title":"Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2022-08-18","conditions":"Neonatal Respiratory Distress Syndrome, Inflammatory Response, Premature Lungs","enrollment":60},{"nctId":"NCT03275415","phase":"PHASE4","title":"Intratracheal Budesonide/Surfactant Prevents BPD","status":"COMPLETED","sponsor":"Taipei Medical University","startDate":"2019-07-01","conditions":"Respiratory Distress Syndrome, Bronchopulmonary Dysplasia","enrollment":310},{"nctId":"NCT05364385","phase":"PHASE4","title":"Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2019-12-02","conditions":"Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity","enrollment":25},{"nctId":"NCT05534685","phase":"NA","title":"Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia","status":"UNKNOWN","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2022-09-20","conditions":"Respiratory Tract Diseases","enrollment":336},{"nctId":"NCT04862377","phase":"PHASE3","title":"Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2021-10-01","conditions":"Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant, Prematurity","enrollment":50},{"nctId":"NCT04019106","phase":"PHASE1, PHASE2","title":"Budesonide With Intratracheal Surfactants in Extremely Preterm Infants","status":"UNKNOWN","sponsor":"University of Manitoba","startDate":"2019-10-15","conditions":"Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant","enrollment":30},{"nctId":"NCT00883532","phase":"PHASE4","title":"Prevention of Chronic Lung Disease (CLD) in Preterm Infants","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2009-04","conditions":"Respiratory Distress Syndrome, Chronic Lung Disease of Prematurity","enrollment":300},{"nctId":"NCT01268215","phase":"PHASE2","title":"Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.","status":"UNKNOWN","sponsor":"East Carolina University","startDate":"2010-07","conditions":"Bronchopulmonary Dysplasia","enrollment":45},{"nctId":"NCT00146497","phase":"PHASE4","title":"Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants","status":"TERMINATED","sponsor":"China Medical University Hospital","startDate":"2004-08","conditions":"Premature Infants, Respiratory Distress Syndrome, Chronic Lung Disease","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Budesonide-Surfactant","genericName":"Budesonide-Surfactant","companyName":"China Medical University Hospital","companyId":"china-medical-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is a corticosteroid that reduces airway inflammation, while the surfactant component improves drug delivery and reduces surface tension in the lungs. Used for Asthma (maintenance and reliever therapy), Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}